Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): A randomized prospective study

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 68-74

  Ali El Dein, Bedeir ^a   El Baz, Mahmoud ^a   Aly, Adel Nabeeh M ^a   Shamaa, Sameh ^a   Ashamallah, Albair ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bladder; Bladder neoplasms; Carcinoma; Doxorubicin; Epirubicin; Transitional cell

Indexed keywords

DOXORUBICIN; EPIRUBICIN;

ARTICLE; BLADDER CARCINOMA; BLADDER CONTRACTION; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSURIA; FEVER; HEMATURIA; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION;

EID: 0030914051     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00018     Document Type: Article

References (28)

1. Herr, H. W. and Laudone, V. P.: Intravesical therapy for superficial bladder cancer. AUA Update Series, vol. VIII, lesson 12, 1989.
2. Shoukry, I.: Management of superficial bladder tumors. Bladder cancer symposium, NCl-ESO, Cairo, Egypt, November 2-4, 1988.
3. Soloway, M. S.: The management of superficial bladder cancer. Cancer, 45: 1856, 1980.
4. Soloway, M.: Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J. Urol., 123: 461, 1980.
5. Matsumura, Y., Ozaki, Y. and Ohmori, H.: Intravesical adriamycin chemotherapy in bladder cancer. Cancer Chemother. Pharmacol., supp., 11: S69, 1983.
6. Niijima, T., Koiso, K. and Akaza, H.: Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother. Pharmacol., supp., 11: S79, 1983.
7. Zincke, H., Utz, D. C., Taylor, W. F., Myers, R. P. and Leary, F. J.: Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol., 129: 505, 1983.
8. Bonfante, V., Villani, F. and Bonnadonna, G.: Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori, 68: 105, 1982.
9. Cumming, J. A., Kirk, D., Newling, D. W., Hargreave, T. B. and Whelan, P.: A multi-centre phase 2 study of intravesical epirubicin in the treatment of superficial bladder tumour. Eur. Urol., 17: 20, 1990.
10. Whelan, P., Cumming, J. A., Garvie, W. H., Hargreave, T. B., Kirk, D., Newling, D. W., Robinson, M. R. and Smith, P. H.: Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups. Brit. J. Urol., 67: 600, 1991.
11. Herr, H. W., Laudone, V. P. and Whitmore, W. F., Jr.: An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138: 1363, 1987.
12. Soloway, M. S.: Intravesical therapy for bladder cancer. Urol. Clin. N. Amer., 15: 661, 1988.
13. Smith, G., Elton, R. A., Beynon, L. L., Newsam, J. E., Chisholm, G. D. and Hargreave, T. B.: Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Brit. J. Urol., 55: 665, 1983.
14. Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R. and Members of the European Organization for Research and Treatment of Cancer Genitourinary Group: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol., 149: 749, 1993.
15. Melekos, M. D., Chionis, H. S., Paranychianakis, G. S. and Dauaher, H. H.: Intravesical 4′-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer, 72: 1749, 1993.
16. Watanabe, N., Miyagawa, I., Higasibori, Y., Nakahara, T., Sumi, F., Ishida, G., Abe, B., Inoue, A. and Hanamoto, N.: Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group. Cancer Chemother. Pharmacol., suppl., 35: S57, 1994.
17. van der Meijden, A. P., Kurth, K. H., Oosterlinck, W. and Debruyne, F. M.: Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother. Pharmacol., suppl., 30: S95, 1992.
18. Abel, P. D., Hall, R. R. and Williams, G.: Should pT1 transitional cell cancers of the bladder still be classified as superficial? Brit. J. Urol., 62: 235, 1988.
19. Carbin, B.-E., Ekman, P., Gustafson, H., Christensen, N. J., Silfverswärd, C. and Sandstedt, B.: Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance. J. Urol., 145: 972, 1991.
20. Garnick, M. B.., Schade, D., Israel, M., Maxwell, B. and Richie, J. P.: Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder cancer. J. Urol., 131: 43, 1984.
21. Matsumura, Y., Tsushima, T., Ozaki, Y., Yoshimoto, J., Akagi, T., Obama, T., Nasu, Y. and Ohmori, H.: Intravesical chemotherapy with 4′-epi-Adriamycin in patients with superficial bladder tumors. Cancer Chemother. Pharmacol., 16: 176, 1986.
22. Shinohara, N., Nonomura, K., Tanaka, M., Nagamori, S., Takakura, F., Seki, T., Koyanagi, T., Togashi, M. and Maru, A.: Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin and pirarubicin) for primary superficial bladder cancer. Hokkaido University Bladder Cancer Collaborative Group. Cancer Chemother. Pharmacol., suppl., 35: S41, 1994.
23. Burk, K., Kurth, K. H. and Newling, D.: Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Progr. Clin. Biol. Res., 303: 423, 1989.
24. Crawford, E. D., McKenzie, D., Mansson, W., Totonchy, M., Grossman, H. B., Davis, M., Lamm, D. L. and Duchek, M.: Adverse reactions to the intravesical administration of doxorubicin hydrochloride. Report of 6 cases. J. Urol., 136: 668, 1986.
25. Kurth, K. H., Schröder, F. H., Tunn, U., Ay, R., Pavone-Macaluso, M., Debruyne, F., de Pauw, M., Dalesio, O., ten Kate, F. and Members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European Organization for Research on Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J. Urol., 132: 258, 1984.
26. Kurth, K. H., v. d. Vijgh, W. J. F., ten Kate, F., Bogdanowicz, J. F., Carpentier, P. J. and van Reyswoud, L: Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J. Urol., 146: 1508, 1991.
27. 3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration. J. Urol., 124: 34, 1980.
28. Edsmyr, F., Berlin, T., Boman, J., Duchek, M., Esposti, P. L., Gustafsson, H., Wijkström, H., and Collste, L. G.: Intravesical therapy with adriamycin in patients with superficial bladder tumors. Eur. Urol., 6: 132, 1980.